Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 17/20 | 0.77 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341136 | 1.00 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL23477127 | 1.00 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL29885238 | 1.00 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL13341164 | 1.00 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL13716183 | 0.94 | STING1 (0.70) | STING1PDE3BPDE3A | |
| SCHEMBL20321040 | 0.94 | STING1 (0.72) | STING1 | |
| SCHEMBL22434632 | 0.93 | STING1 (0.87) | STING1 | |
| SCHEMBL13341166 | 0.91 | STING1 (0.87) | STING1PDE3BPDE3A | |
| SCHEMBL23476871 | 0.91 | STING1 (0.87) | STING1PDE3BPDE3A | |
| SCHEMBL13367629 | 0.91 | STING1 (0.87) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367716-B2 | Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation | KARAOLIS DAVID K R (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1740192-B1 | CYCLIC DINUCLEOTIDE FOR STIMULATING THE IMMUNE OF INFLAMMATORY RESPONSE | KARAOLIS DAVID K R (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7709458-B2 | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | Karaolis, David K. R. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7592326-B2 | Method for stimulating the immune, inflammatory or neuroprotective response | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7592326-B2 | Method for stimulating the immune, inflammatory or neuroprotective response | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7569555-B2 | Method for stimulating the immune, inflammatory or neuroprotective response | KARAGEN PHARMACEUTICALS | 2009-08-04 | — | — | US | disclosed |
| US-7569555-B2 | Method for stimulating the immune, inflammatory or neuroprotective response | KARAGEN PHARMACEUTICALS | 2009-08-04 | — | — | US | disclosed |
| US-20070281897-A1 | METHOD FOR STIMULATING THE IMMUNE, INFLAMMATORY OR NEUROPROTECTIVE RESPONSE | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070244059-A1 | Method For Attentuating Virulence Of Microbial Pathogens And For Inhibiting Microbial Biofilm Formation | KARAOLIS DAVID K | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281897-A1 | METHOD FOR STIMULATING THE IMMUNE, INFLAMMATORY OR NEUROPROTECTIVE RESPONSE | CGAS, STING1, PDE7A | STING1 2/4885PDE3B 21/4885PDE3A 19/4885 |
| US-20070244059-A1 | Method For Attentuating Virulence Of Microbial Pathogens And For Inhibiting Microbial Biofilm Formation | GMPS, CGAS, AMPD1 | STING1 14/4885PDE3B 18/4885PDE3A 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.